Exhibit 99.1
| | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
| (unaudited, in millions, except per share data) |
| | | | | |
| Three Months Ended 1 |
| December 31,
2021 | Percent of
Net sales | | December 25,
2020 | Percent of
Net sales |
| Net sales | $ | 597.2 | | 100.0 | % | | $ | 682.8 | | 100.0 | % |
| Cost of sales | 358.7 | | 60.1 | | | 372.3 | | 54.5 | |
| Gross profit | 238.5 | | 39.9 | | | 310.5 | | 45.5 | |
| Selling, general and administrative expenses | 173.5 | | 29.1 | | | 200.9 | | 29.4 | |
| Research and development expenses | 38.9 | | 6.5 | | | 65.0 | | 9.5 | |
| Restructuring charges, net | 9.4 | | 1.6 | | | 21.7 | | 3.2 | |
| Non-restructuring impairment charges | 90.4 | | 15.1 | | | — | | — | |
| Gains on divestiture | — | | — | | | (6.5) | | (1.0) | |
| Opioid-related litigation settlement gain | — | | — | | | (9.3) | | (1.4) | |
| | | | | |
| Operating (loss) income | (73.7) | | (12.3) | | | 38.7 | | 5.7 | |
| Interest expense | (61.9) | | (10.4) | | | (60.2) | | (8.8) | |
| Interest income | — | | — | | | 0.5 | | 0.1 | |
| | | | | |
| Other income, net | 6.1 | | 1.0 | | | 6.3 | | 0.9 | |
| Reorganization items, net | (99.0) | | (16.6) | | | (61.4) | | (9.0) | |
| Loss from continuing operations before income taxes | (228.5) | | (38.3) | | | (76.1) | | (11.1) | |
| Income tax (benefit) expense | (24.4) | | (4.1) | | | 78.1 | | 11.4 | |
| Loss from continuing operations | (204.1) | | (34.2) | | | (154.2) | | (22.6) | |
| Income from discontinued operations, net of income taxes | 0.1 | | — | | | 1.3 | | 0.2 | |
| Net loss | $ | (204.0) | | (34.2) | % | | $ | (152.9) | | (22.4) | % |
| | | | | |
| Basic loss per share: | | | | | |
| Loss from continuing operations | $ | (2.41) | | | | $ | (1.82) | | |
| Income from discontinued operations | — | | | | 0.02 | | |
| Net loss | $ | (2.41) | | | | $ | (1.81) | | |
| Diluted loss per share: | | | | | |
| Loss from continuing operations | $ | (2.41) | | | | $ | (1.82) | | |
| Income from discontinued operations | — | | | | 0.02 | | |
| Net loss | $ | (2.41) | | | | $ | (1.81) | | |
| Weighted-average number of shares outstanding | | | | | |
| Basic weighted-average shares outstanding | 84.7 | | | 84.6 | |
| Diluted weighted-average shares outstanding | 84.7 | | | 84.6 | |
(1)The Company reports its results based on a "52-53 week" year ending on the last Friday of December. The three months ended December 31, 2021 refers to the fourteen week period ended December 31, 2021 and the three months ended December 25, 2020 refers to the thirteen week period ended December 25, 2020.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| CONSOLIDATED ADJUSTED EBITDA |
| (unaudited, in millions) |
| | | | | | | | | |
| Three Months Ended |
| December 31, 2021 | | December 25, 2020 |
| Gross Profit | SG&A | R&D | Adjusted EBITDA | | Gross Profit | SG&A | R&D | Adjusted EBITDA |
| Net loss | $ | 238.5 | | $ | 173.5 | | $ | 38.9 | | $ | (204.0) | | | $ | 310.5 | | $ | 200.9 | | $ | 65.0 | | $ | (152.9) | |
| Adjustments: | | | | | | | | | |
| Interest expense, net | — | | — | | — | | 61.9 | | | — | | — | | — | | 59.7 | |
| Income taxes | — | | — | | — | | (24.4) | | | — | | — | | — | | 78.1 | |
Depreciation(1) | 18.1 | | (4.2) | | (2.1) | | 24.4 | | | 17.7 | | (18.8) | | (1.8) | | 38.3 | |
| Amortization | 144.4 | | (0.9) | | — | | 145.3 | | | 170.6 | | (0.8) | | — | | 171.4 | |
| Restructuring charges, net | — | | — | | — | | 9.4 | | | — | | — | | — | | 21.7 | |
| Non-restructuring impairment charge | — | | — | | — | | 90.4 | | | — | | — | | — | | — | |
| Income from discontinued operations | — | | — | | — | | (0.1) | | | — | | — | | — | | (1.3) | |
| Change in contingent consideration fair value | — | | (0.2) | | — | | 0.2 | | | — | | (7.5) | | — | | 7.5 | |
Significant legal and environmental charges (2) | — | | (34.3) | | — | | 34.3 | | | 0.9 | | (2.6) | | — | | (5.8) | |
| Gains on divestiture | — | | — | | — | | — | | | — | | — | | — | | (6.5) | |
| Separation costs | — | | (0.2) | | — | | 0.2 | | | — | | (18.4) | | — | | 18.4 | |
| | | | | | | | | |
| Unrealized gain on equity investment | — | | — | | — | | 0.1 | | | — | | — | | — | | (1.6) | |
| | | | | | | | | |
| Reorganization items, net | — | | — | | — | | 99.0 | | | — | | — | | — | | 61.4 | |
| Share-based compensation | 0.1 | | (1.5) | | (0.2) | | 1.8 | | | 0.4 | | (6.0) | | (1.3) | | 7.7 | |
| Japanese consumption tax credit | — | | — | | — | | (6.8) | | | — | | — | | — | | — | |
| As adjusted: | $ | 401.1 | | $ | 132.2 | | $ | 36.6 | | $ | 231.7 | | | $ | 500.1 | | $ | 146.8 | | $ | 61.9 | | $ | 296.1 | |
| | | | | | | | | |
(1)Includes $0.1 million and $12.3 million of accelerated depreciation in selling general and administrative expenses ("SG&A") related to restructuring charges incurred during the three months ended December 31, 2021 and December 25, 2020, respectively.
(2)Represents an increase in environmental liabilities during the three months ended December 31, 2021. The three months ended December 25, 2020 includes a $9.3 million decrease in the fair value of the opioid settlement warrants, partially offset by $2.6 million in opioid defense costs and a $0.9 million change to the retrospective Medicaid lawsuit liability.
| | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SEGMENT OPERATING INCOME |
| (unaudited, in millions) |
| | | |
| Three Months Ended |
| December 31,
2021 | | December 25,
2020 |
| Specialty Brands | $ | 224.2 | | | $ | 250.7 | |
| Specialty Generics | 34.1 | | | 50.9 | |
| Segment operating income | 258.3 | | | 301.6 | |
| Unallocated amounts: | | | |
Corporate and unallocated expenses (1) | (60.5) | | | (13.8) | |
| Depreciation and amortization | (169.7) | | | (209.7) | |
| Share-based compensation | (1.8) | | | (7.7) | |
| Restructuring charges, net | (9.4) | | | (21.7) | |
| Non-restructuring impairment charges | (90.4) | | | — | |
| Separation costs | (0.2) | | | (18.4) | |
| | | |
| Opioid-related litigation settlement gain | — | | | 9.3 | |
| Medicaid lawsuit | — | | | (0.9) | |
| Operating (loss) income | $ | (73.7) | | | $ | 38.7 | |
(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH |
| (unaudited, in millions) |
| | | | | | | | | |
| Three Months Ended | | | | | | |
| December 31,
2021 | | December 25,
2020 | | Percent
change | | Currency impact | | Constant-currency growth |
| Specialty Brands | $ | 397.4 | | | $ | 506.6 | | | (21.6) | % | | (0.1) | % | | (21.5) | % |
| Specialty Generics | 199.8 | | | 177.1 | | | 12.8 | | | 0.1 | | | 12.7 | |
| Segment net sales | 597.2 | | | 683.7 | | | (12.7) | | | (0.1) | | | (12.6) | |
| Medicaid lawsuit | — | | | (0.9) | | | * | | * | | * |
| Net sales | $ | 597.2 | | | $ | 682.8 | | | (12.5) | % | | (0.1) | % | | (12.4) | % |
*Not meaningful
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH |
| (unaudited, in millions) |
| | | | | | | | | |
| Three Months Ended | | | | | | |
| December 31,
2021 | | December 25,
2020 | | Percent
change | | Currency impact | | Constant-currency growth |
| Specialty Brands | | | | | | | | | |
| Acthar Gel | $ | 169.7 | | | $ | 191.3 | | | (11.3) | % | | — | % | | (11.3) | % |
| INOmax | 110.2 | | | 135.6 | | | (18.7) | | | — | | | (18.7) | |
| Ofirmev | 4.9 | | | 60.5 | | | (91.9) | | | — | | | (91.9) | |
| Therakos | 68.7 | | | 64.5 | | | 6.5 | | | (0.9) | | | 7.4 | |
| Amitiza | 41.1 | | | 50.6 | | | (18.8) | | | — | | | (18.8) | |
| Other | 2.8 | | | 4.1 | | | (31.7) | | | — | | | (31.7) | |
| Specialty Brands Total | 397.4 | | | 506.6 | | | (21.6) | | | (0.1) | | | (21.5) | |
| | | | | | | | | |
| Specialty Generics | | | | | | | | | |
| Hydrocodone (API) and hydrocodone-containing tablets | 22.0 | | | 26.1 | | | (15.7) | | | — | | | (15.7) | |
| Oxycodone (API) and oxycodone-containing tablets | 19.0 | | | 20.4 | | | (6.9) | | | — | | | (6.9) | |
| Acetaminophen (API) | 69.1 | | | 58.5 | | | 18.1 | | | — | | | 18.1 | |
| Other controlled substances | 84.8 | | | 66.1 | | | 28.3 | | | 0.2 | | | 28.1 | |
| Other | 4.9 | | | 6.0 | | | (18.3) | | | — | | | (18.3) | |
| Specialty Generics Total | 199.8 | | | 177.1 | | | 12.8 | | | 0.1 | | | 12.7 | |
| Segment net sales | 597.2 | | | 683.7 | | | (12.7) | | | (0.1) | | | (12.6) | |
| Medicaid lawsuit | — | | | (0.9) | | | * | | * | | * |
| Net sales | $ | 597.2 | | | $ | 682.8 | | | (12.5) | % | | (0.1) | % | | (12.4) | % |
*Not meaningful
| | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
| (unaudited, in millions, except per share data) |
| | | | | |
| Fiscal Year 1 |
| December 31,
2021 | Percent of
Net sales | | December 25,
2020 | Percent of
Net sales |
| Net sales (includes refined estimate of the retrospective one-time charge of $536.0 related to the Medicaid lawsuit for the fiscal year ended December 25, 2020) | $ | 2,208.8 | | 100.0 | % | | $ | 2,213.4 | | 100.0 | % |
| Cost of sales | 1,317.1 | | 59.6 | | | 1,544.0 | | 69.8 | |
| Gross profit | 891.7 | | 40.4 | | | 669.4 | | 30.2 | |
| Selling, general and administrative expenses | 581.8 | | 26.3 | | | 884.1 | | 39.9 | |
| Research and development expenses | 205.2 | | 9.3 | | | 290.8 | | 13.1 | |
| Restructuring charges, net | 26.9 | | 1.2 | | | 37.5 | | 1.7 | |
| Non-restructuring impairment charges | 154.9 | | 7.0 | | | 63.5 | | 2.9 | |
| Losses (gains) on divestiture | 0.8 | | — | | | (16.6) | | (0.7) | |
| Opioid-related litigation settlement loss (gain) | 125.0 | | 5.7 | | | (43.4) | | (2.0) | |
| Medicaid lawsuit | — | | — | | | 105.1 | | 4.7 | |
| Operating loss | (202.9) | | (9.2) | | | (651.6) | | (29.4) | |
| Interest expense | (222.6) | | (10.1) | | | (261.1) | | (11.8) | |
| Interest income | 1.9 | | 0.1 | | | 5.9 | | 0.3 | |
| | | | | |
| Other income, net | 22.0 | | 1.0 | | | 7.4 | | 0.3 | |
| Reorganization items, net | (428.2) | | (19.4) | | | (61.4) | | (2.8) | |
| Loss from continuing operations before income taxes | (829.8) | | (37.6) | | | (960.8) | | (43.4) | |
| Income tax (benefit) expense | (106.3) | | (4.8) | | | 8.9 | | 0.4 | |
| Loss from continuing operations | (723.5) | | (32.8) | | | (969.7) | | (43.8) | |
| Income from discontinued operations, net of income taxes | 6.1 | | 0.3 | | | 25.1 | | 1.1 | |
| Net loss | $ | (717.4) | | (32.5) | % | | $ | (944.6) | | (42.7) | % |
| | | | | |
| Basic loss per share: | | | | | |
| Loss from continuing operations | $ | (8.54) | | | | $ | (11.48) | | |
| Income from discontinued operations | 0.07 | | | | 0.30 | | |
| Net loss | $ | (8.47) | | | | $ | (11.18) | | |
| Diluted loss per share: | | | | | |
| Loss from continuing operations | $ | (8.54) | | | | $ | (11.48) | | |
| Income from discontinued operations | 0.07 | | | | 0.30 | | |
| Net loss | $ | (8.47) | | | | $ | (11.18) | | |
| Weighted-average number of shares outstanding: | | | | | |
| Basic | 84.7 | | | 84.5 | |
| Diluted | 84.7 | | | 84.5 | |
| | | | | |
| | | | | |
(1)The Company reports its results based on a "52-53 week" year ending on the last Friday of December. Fiscal 2021 consisted of 53 weeks and fiscal 2020 consisted of 52 weeks.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| CONSOLIDATED ADJUSTED EBITDA |
| (unaudited, in millions) |
| Fiscal Year |
| December 31, 2021 | | December 25, 2020 |
| Gross Profit | SG&A | R&D | Adjusted EBITDA | | Gross Profit | SG&A | R&D | Adjusted EBITDA |
| Net loss | $ | 891.7 | | $ | 581.8 | | $ | 205.2 | | $ | (717.4) | | | $ | 669.4 | | $ | 884.1 | | $ | 290.8 | | $ | (944.6) | |
| Adjustments: | | | | | | | | | |
| Interest expense, net | — | | — | | — | | 220.7 | | | — | | — | | — | | 255.2 | |
| Income taxes | — | | — | | — | | (106.3) | | | — | | — | | — | | 8.9 | |
Depreciation(1) | 70.3 | | (17.6) | | (6.8) | | 94.7 | | | 71.9 | | (35.1) | | (7.0) | | 114.0 | |
| Amortization | 577.7 | | (3.4) | | — | | 581.1 | | | 767.8 | | (3.4) | | — | | 771.2 | |
| Restructuring charges, net | — | | — | | — | | 26.9 | | | — | | — | | — | | 37.5 | |
| Non-restructuring impairment charge | — | | — | | — | | 154.9 | | | — | | — | | — | | 63.5 | |
| Income from discontinued operations | — | | — | | — | | (6.1) | | | — | | — | | — | | (25.1) | |
| Change in contingent consideration fair value | — | | 7.4 | | — | | (7.4) | | | — | | (9.9) | | — | | 9.9 | |
Significant legal and environmental charges (2) | — | | (34.3) | | — | | 159.3 | | | 536.0 | | (55.7) | | — | | 653.4 | |
| Losses (gains) on divestiture | — | | — | | — | | 0.8 | | | — | | — | | — | | (16.6) | |
| Separation costs | — | | (1.2) | | — | | 1.2 | | | — | | (93.4) | | — | | 93.4 | |
| | | | | | | | | |
| Unrealized gain on equity investment | — | | — | | — | | (4.7) | | | — | | — | | — | | (3.8) | |
| R&D upfront payment | — | | — | | — | | — | | | — | | — | | (5.0) | | 5.0 | |
| Reorganization items, net | — | | — | | — | | 428.2 | | | — | | — | | — | | 61.4 | |
| Share-based compensation | 0.5 | | (8.1) | | (1.6) | | 10.2 | | | 1.3 | | (19.9) | | (4.1) | | 25.3 | |
| Japanese consumption tax credit | — | | — | | — | | (6.8) | | | — | | — | | — | | — | |
| As adjusted: | $ | 1,540.2 | | $ | 524.6 | | $ | 196.8 | | $ | 829.3 | | | $ | 2,046.4 | | $ | 666.7 | | $ | 274.7 | | $ | 1,108.6 | |
(1)Includes $2.1 million and $12.3 million of accelerated depreciation in SG&A related to restructuring charges incurred during fiscal 2021 and 2020, respectively.
(2)Fiscal 2021 includes a $125.0 million charge related to the opioid-related litigation settlement liability and a $34.3 million increase in environmental liabilities. Fiscal 2020 includes a retrospective one-time charge of $641.1 million (the "Acthar Gel Medicaid Retrospective Rebate"), of which $536.0 million and $105.1 million have been reflected as a component of net sales and operating expenses, respectively, in the condensed consolidated statement of operations. The $105.1 million reflected as a component of operating expenses represents a pre-acquisition contingency related to the portion of the Acthar Gel Medicaid Retrospective Rebate that arose from sales of Acthar Gel prior to the Company’s acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Fiscal 2020 also includes $55.7 million of opioid defense costs, partially offset by a $43.4 million decrease in the fair value of the opioid settlement warrants.
| | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SEGMENT OPERATING INCOME |
| (unaudited, in millions) |
| | | |
| Fiscal Year |
| December 31,
2021 | | December 25,
2020 |
| Specialty Brands | $ | 812.8 | | | $ | 1,015.7 | |
| Specialty Generics | 107.9 | | | 206.4 | |
| Segment operating income | 920.7 | | | 1,222.1 | |
| Unallocated amounts: | | | |
Corporate and unallocated expenses (1) | (129.6) | | | (166.1) | |
| Depreciation and amortization | (675.8) | | | (885.2) | |
| Share-based compensation | (10.2) | | | (25.3) | |
| Restructuring charges, net | (26.9) | | | (37.5) | |
| Non-restructuring impairment charges | (154.9) | | | (63.5) | |
| Separation costs | (1.2) | | | (93.4) | |
| R&D upfront payment | — | | | (5.0) | |
| Opioid-related litigation settlement (loss) gain | (125.0) | | | 43.4 | |
| Medicaid lawsuit | — | | | (641.1) | |
| Operating loss | $ | (202.9) | | | $ | (651.6) | |
(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH |
| (unaudited, in millions) |
| | | | | | | | | |
| Fiscal Year | | | | | | |
| December 31,
2021 | | December 25,
2020 | | Percent
change | | Currency impact | | Constant-currency growth |
| Specialty Brands | $ | 1,547.0 | | | $ | 2,059.6 | | | (24.9) | % | | 0.2 | % | | (25.1) | % |
| Specialty Generics | 661.8 | | | 689.8 | | | (4.1) | | | 0.1 | | | (4.2) | |
| Segment net sales | 2,208.8 | | | 2,749.4 | | | (19.7) | | | 0.2 | | | (19.9) | |
| Medicaid lawsuit | — | | | (536.0) | | | * | | * | | * |
| Net sales | $ | 2,208.8 | | | $ | 2,213.4 | | | (0.2) | % | | 0.2 | % | | (0.4) | % |
*Not meaningful
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| SELECT PRODUCT LINE NET SALES |
| (unaudited, in millions) |
| | | | | | | | | |
| Fiscal Year | | | | | | |
| December 31,
2021 | | December 25,
2020 | | Percent
change | | Currency impact | | Constant-currency growth |
| Specialty Brands | | | | | | | | | |
| Acthar | $ | 593.6 | | | $ | 767.9 | | | (22.7) | % | | — | % | | (22.7) | % |
| INOmax | 448.5 | | | 574.1 | | | (21.9) | | | 0.1 | | | (22.0) | |
| Ofirmev | 28.9 | | | 276.5 | | | (89.5) | | | — | | | (89.5) | |
| Therakos | 266.5 | | | 238.6 | | | 11.7 | | | 1.3 | | | 10.4 | |
| Amitiza | 196.9 | | | 188.8 | | | 4.3 | | | — | | | 4.3 | |
| Other | 12.6 | | | 13.7 | | | (8.0) | | | — | | | (8.0) | |
| Specialty Brands Total | 1,547.0 | | | 2,059.6 | | | (24.9) | | | 0.2 | | | (25.1) | |
| | | | | | | | | |
| Specialty Generics | | | | | | | | | |
| Hydrocodone (API) and hydrocodone-containing tablets | 82.7 | | | 98.0 | | | (15.6) | | | — | | | (15.6) | |
| Oxycodone (API) and oxycodone-containing tablets | 68.5 | | | 68.4 | | | 0.1 | | | — | | | 0.1 | |
| Acetaminophen (API) | 215.9 | | | 213.0 | | | 1.4 | | | — | | | 1.4 | |
| Other controlled substances | 272.7 | | | 289.9 | | | (5.9) | | | 0.3 | | | (6.2) | |
| Other | 22.0 | | | 20.5 | | | 7.3 | | | — | | | 7.3 | |
| Specialty Generics Total | 661.8 | | | 689.8 | | | (4.1) | | | 0.1 | | | (4.2) | |
| Segment net sales | 2,208.8 | | | 2,749.4 | | | (19.7) | | | 0.2 | | | (19.9) | |
| Medicaid lawsuit | — | | | (536.0) | | | * | | * | | * |
| Net sales | $ | 2,208.8 | | | $ | 2,213.4 | | | (0.2) | % | | 0.2 | % | | (0.4) | % |
*Not meaningful
| | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| CONDENSED CONSOLIDATED BALANCE SHEETS |
| (unaudited, in millions) |
| | | |
| December 31,
2021 | | December 25,
2020 |
| Assets | | | |
| Current Assets: | | | |
| Cash and cash equivalents | $ | 1,345.0 | | | $ | 1,070.6 | |
| Accounts receivable, net | 439.1 | | | 538.8 | |
| Inventories | 347.2 | | | 344.9 | |
| Prepaid expenses and other current assets | 178.3 | | | 350.0 | |
| | | |
| Total current assets | 2,309.6 | | | 2,304.3 | |
| Property, plant and equipment, net | 776.0 | | | 833.1 | |
| Intangible assets, net | 5,448.4 | | | 6,184.5 | |
| Other assets | 382.3 | | | 393.5 | |
| Total Assets | $ | 8,916.3 | | | $ | 9,715.4 | |
| | | |
| Liabilities and Shareholders' Equity | | | |
| Current Liabilities: | | | |
| Current maturities of long-term debt | $ | 1,388.9 | | | $ | 3,587.9 | |
| Accounts payable | 123.0 | | | 93.3 | |
| Accrued payroll and payroll-related costs | 84.6 | | | 79.4 | |
| Accrued interest | 17.0 | | | 26.9 | |
| Accrued and other current liabilities | 328.7 | | | 331.2 | |
| | | |
| Total current liabilities | 1,942.2 | | | 4,118.7 | |
| | | |
| | | |
| Pension and postretirement benefits | 30.1 | | | 34.6 | |
| Environmental liabilities | 43.0 | | | 59.8 | |
| Deferred income taxes | 20.9 | | | 80.6 | |
| Other income tax liabilities | 83.2 | | | 100.1 | |
| Other liabilities | 85.8 | | | 109.8 | |
| Liabilities subject to compromise | 6,397.7 | | | 4,192.6 | |
| Total Liabilities | 8,602.9 | | | 8,696.2 | |
| Shareholders' Equity: | | | |
| Preferred shares | — | | | — | |
| Ordinary shares | 18.9 | | | 18.8 | |
| Ordinary shares held in treasury at cost | (1,616.1) | | | (1,616.1) | |
| Additional paid-in capital | 5,597.8 | | | 5,587.6 | |
| Retained deficit | (3,678.9) | | | (2,961.5) | |
| Accumulated other comprehensive loss | (8.3) | | | (9.6) | |
| Total Shareholders' Equity | 313.4 | | | 1,019.2 | |
| Total Liabilities and Shareholders' Equity | $ | 8,916.3 | | | $ | 9,715.4 | |
| | | | | | | | | | | |
| MALLINCKRODT PLC |
| (DEBTOR-IN-POSSESSION) |
| (IN EXAMINATION UNDER PART 10 OF THE IRISH COMPANIES ACT 2014) |
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
| (unaudited, in millions) |
| | | |
| Fiscal Year |
| December 31,
2021 | | December 25,
2020 |
| Cash Flows From Operating Activities: | | | |
| Net loss | $ | (717.4) | | | $ | (944.6) | |
| Adjustments to reconcile net cash from operating activities: | | | |
| Depreciation and amortization | 675.8 | | | 885.2 | |
| Share-based compensation | 10.2 | | | 25.3 | |
| Deferred income taxes | (59.9) | | | 385.3 | |
| Non-cash impairment charges | 154.9 | | | 63.5 | |
| Inventory provisions | 11.5 | | | 18.5 | |
| Losses (gains) on divestiture | 0.8 | | | (16.6) | |
| | | |
| | | |
| Other non-cash items | (13.1) | | | (40.2) | |
| Reorganization items, net | 22.5 | | | 10.2 | |
| Changes in assets and liabilities: | | | |
| Accounts receivable, net | 98.2 | | | 37.9 | |
| Inventories | (14.0) | | | (51.1) | |
| Accounts payable | (1.1) | | | 15.7 | |
| Income taxes | 108.5 | | | (433.8) | |
| Opioid-related litigation settlement liability | 125.0 | | | — | |
| Medicaid lawsuit | (4.2) | | | 638.9 | |
| Other | 57.7 | | | (95.3) | |
| Net cash from operating activities | 455.4 | | | 498.9 | |
| Cash Flows From Investing Activities: | | | |
| Capital expenditures | (55.3) | | | (47.7) | |
| | | |
| Proceeds (payments) related to divestiture, net of cash | 15.7 | | | (0.7) | |
| Other | 1.8 | | | 37.2 | |
| Net cash from investing activities | (37.8) | | | (11.2) | |
| Cash Flows From Financing Activities: | | | |
| | | |
| Repayment of external debt | (137.5) | | | (139.5) | |
| Debt financing costs | — | | | (9.4) | |
| | | |
| Repurchase of shares | — | | | (0.4) | |
| Other | — | | | (36.3) | |
| Net cash from financing activities | (137.5) | | | (185.6) | |
| Effect of currency rate changes on cash | (1.9) | | | 2.3 | |
| Net change in cash, cash equivalents and restricted cash | 278.2 | | | 304.4 | |
| Cash, cash equivalents and restricted cash at beginning of period | 1,127.0 | | | 822.6 | |
| Cash, cash equivalents and restricted cash at end of period | $ | 1,405.2 | | | $ | 1,127.0 | |
| | | |
| Cash and cash equivalents at end of period | $ | 1,345.0 | | | $ | 1,070.6 | |
| Restricted cash included in prepaid expenses and other assets at end of period | 24.0 | | | 20.2 | |
| Restricted cash included in other long-term assets at end of period | 36.2 | | | 36.2 | |
| Cash, cash equivalents and restricted cash at end of period | $ | 1,405.2 | | | $ | 1,127.0 | |
